86 studies on THYMOSIN-ALPHA-1 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently curates 86 dated studies on THYMOSIN-ALPHA-1. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $15.00 | $13.00–$17.00 | $3.00 | 2 sources · 2 offers |
| 10 mg | $22.50 | $19.50–$25.00 | $2.25 | 3 sources · 3 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
This research uncovers a novel, indirect antitumor mechanism for Thymosin alpha-1 that goes beyond general immune modulation. For individuals using TA in cancer support protocols, this suggests a specific benefit in d…
If successful, this trial could establish **Thymosin alpha 1 as a first-line preventative therapy for infected pancreatic necrosis (IPN)**, a deadly complication of acute pancreatitis. This would represent a major shi…
This research suggests Tα1 could be a valuable adjunct therapy for managing the systemic, non-pulmonary complications of Cystic Fibrosis (CF). For patients and clinicians, this points to a potential strategy for addre…
This research implies that the effectiveness of immunomodulatory peptides like Thymosin alpha-1 may not be uniform across genders. For individuals using Tα1 for immune support, particularly in the context of viral inf…
This study challenges the widespread use of thymosin α1 as a standard adjunctive therapy for critically ill COVID-19 patients. For clinicians and individuals considering its use in similar viral-induced critical illne…
This comprehensive review underscores the significant, yet often underappreciated, therapeutic potential of Thymosin alpha 1 as a broad-spectrum immune modulator with direct antiviral capabilities. The findings strong…
This research provides a powerful proof-of-concept for a next-generation, long-acting Thymosin α1. For clinicians and patients, this could mean a shift from frequent, burdensome injections to a much more manageable do…
These findings provide a mechanistic rationale for using **Thymosin alpha 1 (Tα1)** in the management of **COVID-19** and potentially other conditions characterized by a cytokine storm. For clinicians and individuals …
For individuals considering Thymosin-α1 as an adjunctive therapy for mild or moderate viral illnesses, this study provides a nuanced perspective. The findings suggest that Tα1 may not be the preventative agent against…
This study provides a preclinical rationale for combining the immunomodulatory peptide **Thymosin alpha 1** with the chemotherapeutic agent Gemcitabine for treating **NNKTL**. The synergy suggests that Tα1 may enhance…
**Postpartum patients on ECMO represent one of the highest-complexity critical care scenarios**, combining altered coagulation physiology, postoperative hemodynamics, and immune dysregulation driven by COVID-19. The i…
This unique case highlights the critical need to understand atypical immune responses in immunocompromised individuals with SARS-CoV-2 and other viral infections. The absence of antibody production in this long-term a…
This review underscores the significant potential of Thymosin α-1 (Tα-1) to revolutionize cancer treatment strategies. By enhancing the body's natural anti-tumor immune response and potentially mitigating the side eff…
This systematic review underscores the significant therapeutic potential of thymosin drugs as a valuable addition to the current arsenal against lung cancer. Their ability to modulate the immune system offers a distin…
Acute type A aortic dissection (ATAAD) surgery carries a high risk of complications, and current treatments lack targeted strategies for immune modulation to prevent organ failure. A successful outcome for the PANDA I…
The development of Refnot represents a significant advancement, offering a novel and potentially safer strategy to combat the multifaceted challenges of age-related immune decline and chronic inflammation. By combinin…
This compelling case report underscores the critical need for heightened clinical vigilance and careful patient selection when considering combination therapies involving immune checkpoint inhibitors and other immunom…
Understanding the exact chemical structure of Thymosin Alpha-1 is an absolutely crucial first step for any scientific investigation into its potential biological roles or therapeutic applications. This foundational ch…
The withdrawal of this study highlights the inherent challenges in conducting clinical trials, especially for complex conditions like metastatic colorectal cancer where new treatment strategies are desperately needed.…
Free, no account — handy when you're working with THYMOSIN-ALPHA-1.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account